Success Metrics

Active Trials

3(50%)

Phase Distribution

Ph phase_1

83%

Ph phase_3

17%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

5(83.3%)

Phase 3Large-scale testing

1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Other(3)

Detailed Status

unknown3

Recruiting2

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 3

Trials by Phase

Phase 15 (83.3%)

Phase 31 (16.7%)

Trials by Status

active_not_recruiting117%

recruiting233%

unknown350%

Recent Activity

3 active trials

Showing 5 of 6

recruitingphase_1

A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.

NCT07392736

active_not_recruitingphase_1

Clinical Trials (6)

Showing 6 of 6 trials

NCT07392736Phase 1

A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.

Recruiting

NCT06794957Phase 1

A Study of AL8326 in Non-Small Cell Lung Cancer

Active Not Recruiting

NCT06247605Phase 3

A Phase IIII Study of AL8326 in Small Cell Lung Cancer

Recruiting

NCT05486598Phase 1

A Study of Diet Influence of AL8326 in Chinese Healthy Adult Subjects

Unknown

NCT04890587Phase 1

A Phase I Study of AL8326 in Advanced Solid Tumor

Unknown

NCT04890795Phase 1

A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer

Unknown

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6